VYEPTI permanent J-code (J3032) is now available. Learn more

Powerful migraine prevention*

*In patients who have 8 or more monthly migraine days.1 One month was defined as 28 consecutive days.2

Meet Electra, a real patient with chronic migraine treated with VYEPTI
icon quotemarks coral 64px

“The migraine attacks were debilitating. I couldn’t function.”

Meet Electra, a real patient with chronic migraine treated with VYEPTI

Meet Electra†‡

Age: 37 years old

Sex: Female

Diagnosis: Chronic migraine

Treatment Concerns: Increasing use of acute medications

Impact: Missing work and time with family

†A real VYEPTI patient. Patient results may vary. VYEPTI may not work for everyone. Electra was compensated for sharing her story.
‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgment.

Migraine had taken over Electra’s life

  • Eight or more migraine days a month
  • Migraine with nausea, light sensitivity, and mental fog
  • Disruption of family life
  • Inability to plan ahead
  • Missed work days
icon quotemarks coral 64px

“The migraine attacks were debilitating. I couldn’t function.”

She was losing hope

  • Acute medications required with greater frequency
  • Occasional need to visit the emergency room
  • Tried >2 preventive treatments
  • Stopped treatments due to lack of efficacy and/or side effects
icon quotemarks coral 64px

“I love the IV… It’s easy to just get this once every 3 months and then be on my way.”1

VYEPTI is administered as one 30-minute IV infusion every 3 months.1

Watch Electra’s video to learn more about her life with migraine

AHS Symposium Cut V 12LR
Electra, outside with her two young adult sons

Consider VYEPTI for your patients like Electra

With one 30-minute IV every 3 months, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1

TALK TO YOUR PATIENTS ABOUT TREATMENT WITH VYEPTI

Learn more about VYEPTI in chronic migraine

CHRONIC MIGRAINE STUDY DESIGN
CHRONIC MIGRAINE RESULTS

You may also be interested in:

DOSING AND ADMINISTRATION
REGISTER FOR UPDATES
SAFETY DATA
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377.

© 2021 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are registered trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v7

This website is intended for US healthcare professionals only.

Site Map Terms of Use Privacy Policy Contact Us